Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc.
Posts Tagged ‘NASDAQ:HALO’
Q2 Earnings Blowouts: 37 Stocks That Beat Expectations
The ongoing earnings season has been a boon to listed companies' share prices in the second quarter of the year, helping offset macroeconomic uncertainties such as the US-Iran...
8 Most Undervalued Growth Stocks to Buy for the Next 10 Years
Growth stocks aren’t supposed to be cheap. Investors willingly pay higher multiples for companies that are expected to grow earnings over the next few years.
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best healthcare stocks to buy for the long term. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript May 11, 2026Halozyme Therapeutics, Inc. beats earnings expectations.
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Halozyme Therapeutics, Inc. is one of the best cancer stocks to invest in.
10 Best Healthcare Stocks to Buy for the Long Term
In this article, we will look at the 10 Best Healthcare Stocks to Buy for the Long Term.
10 Best Cancer Stocks to Buy for the Long Term
In this article, we will be taking a look at the 10 Best Cancer Stocks to Buy for the Long Term.
Halozyme (HALO) Rated Buy on Strong Royalty Growth
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc.
8 Most Undervalued Biotech Stocks to Buy Right Now
In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now.
9 Most Undervalued Growth Stocks to Buy According to Analysts
In this article, we explore the 9 Most Undervalued Growth Stocks to Buy According to Analysts.
Is Halozyme Therapeutics (HALO) a Buy Post Earnings?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best cheap biotech stocks to buy now. Halozyme Therapeutics, Inc.
12 Cheap Biotech Stocks to Buy Now
In this article, we will look at the 12 Cheap Biotech Stocks to Buy Now.
Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory
We came across a bullish thesis on Halozyme Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on HALO.
Halozyme (HALO) Loses 9% on Weak Earnings
We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026Halozyme Therapeutics, Inc. misses on earnings expectations.
H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the 11 Best Stocks to Buy for Investment. On January 9, H.C.
11 Best Stocks to Buy for Investment
In this article, we will take a look at the 11 Best Stocks to Buy for Investment.
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance
Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the best mid-cap growth stocks to buy right now.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered...
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the 10 best new stocks to buy in Ray Dalio’s portfolio. On January 8, TD Cowen boosted Halozyme Therapeutics, Inc.
Ray Dalio Stock Portfolio: 10 New Stock Picks
In this article, we will take a look at Billionaire Ray Dalio's new stocks picks.
Here’s What Analysts Think About Halozyme Therapeutics (HALO)
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc.
7 Affordable Stocks With Good Earnings Growth for 2026
In this article, we will look at the 7 Affordable Stocks With Good Earnings Growth for 2026.
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) Following Appreciation
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here’s Why
We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc.
10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade
In this article, we will take a detailed look at the 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2025 Earnings Call Transcript November 3, 2025Halozyme Therapeutics, Inc. beats earnings expectations.
H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C.
9 Most Profitable Biotech Stocks to Buy
In this article, we will look at the 9 Most Profitable Biotech Stocks to Buy.
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc.
14 Best Biotech Stocks to Buy Right Now
In this article, we will take a look at the 14 Best Biotech Stocks to Buy Right Now. The biotech industry is almost always buzzing.
Where is Halozyme Therapeutics (HALO) Headed According to Analysts?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable biotech stocks to invest in now.
12 Affordable Biotech Stocks to Invest In Now
In this article, we will look at the top 12 Affordable Biotech Stocks to Invest In Now.
Halozyme Therapeutics, Inc. (HALO) Hikes 2025 Guidance on ENHANZE Demand
We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Halozyme Therapeutics, Inc. is one of them. Halozyme Therapeutics, Inc.
Morgan Stanley Raises PT on Halozyme Therapeutics (HALO) to $80 From $75
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best high growth low PE stocks to invest in now.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
In this article, we will look at the 13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
In this article, we will be taking a look at the 11 Cheap Biotech Stocks to Buy According to Hedge Funds.
13 High Growth Low PE Stocks to Invest In Now
In this article, we will look at the 13 High Growth Low PE Stocks to Invest In Now.
Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C.
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
10 Most Undervalued Biotech Stocks to Buy Now
In this article, we will look at the 10 Most Undervalued Biotech Stocks to Buy Now.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good afternoon.
Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to invest in now.
10 Most Profitable Biotech Stocks to Invest in Now
In this article, we will look at the 10 Most Profitable Biotech Stocks to Invest in Now.
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center
